-Advertisement-
-Advertisement-
Retinopathy of Prematurity
Premature infants receiving ROP treatment show personal-social development delay
Premature infants treated for Type 1 retinopathy of prematurity (ROP) and aggressive ROP (A-ROP) with intravitreal bevacizumab (IVB) and intravitreal aflibercept (IVA) may experience delay in personal and social development compared to untreated infants, according to a study. The prospective-controlled study, encompassed 3 groups: those treated with intravitreal bevacizumab (IVB,...
Read More-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
[email protected]
© 2023 Ophthalmology 360® is a trademark of International Healthcare Media, LLC. All rights Reserved